Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;51(9):1714-1723.
doi: 10.1007/s00247-021-05037-4. Epub 2021 Apr 20.

Diffusion-weighted imaging in differentiating mid-course responders to chemotherapy for long-bone osteosarcoma compared to the histologic response: an update

Affiliations

Diffusion-weighted imaging in differentiating mid-course responders to chemotherapy for long-bone osteosarcoma compared to the histologic response: an update

Céline Habre et al. Pediatr Radiol. 2021 Aug.

Abstract

Background: Diffusion-weighted imaging (DWI) has been described to correlate with tumoural necrosis in response to preoperative chemotherapy for osteosarcoma.

Objective: To assess the accuracy of DWI in evaluating the response to neoadjuvant chemotherapy at the mid-course treatment of long-bone osteosarcoma and in predicting survival.

Materials and methods: We conducted a prospective single-centre study over a continuous period of 11 years. Consecutive patients younger than 20 years treated with a neoadjuvant regimen for peripheral conventional osteosarcoma were eligible for inclusion. Magnetic resonance imaging (MRI) with DWI was performed at diagnosis, and mid- and end-course chemotherapy with mean apparent diffusion coefficients (ADC) calculated at each time point. A percentage less than or equal to 10% of the viable residual tissue at the histological analysis of the surgical specimen was defined as a good responder to chemotherapy. Survival comparisons were calculated using the Kaplan-Meier method. Uni- and multivariate analyses with ADC change were performed by Cox modelling. This is an expansion and update of our previous work.

Results: Twenty-six patients between the ages of 4.8 and 19.6 years were included, of whom 14 were good responders. At mid-course chemotherapy, good responders had significantly higher mean ADC values (P=0.046) and a higher increase in ADC (P=0.015) than poor responders. The ADC change from diagnosis to mid-course MRI did not appear to be a prognosticator of survival and did not impact survival rates of both groups.

Conclusion: DWI at mid-course preoperative chemotherapy for osteosarcoma should be considered to evaluate the degree of histological necrosis and to predict survival. The anticipation of a response to neoadjuvant treatment by DWI may have potential implications on preoperative management.

Keywords: Bone neoplasm; Children; Diffusion-weighted imaging; Magnetic resonance imaging; Osteosarcoma; Therapeutic response.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Fig. 1
Fig. 1
Osteosarcoma of the proximal tibial metaphysis with extension to physis, epiphysis and joint surface in a 9.5-year-old boy (patient 17). a−f Coronal planes acquired at T1-W (a, d), DWI at b0 value (b, e) and corresponding apparent diffusion coefficient (ADC) maps (c, f). Examples of ADC calculation (good responder) at MRI-1 (a, b, c) and MRI-2 (d, e, f): a region of interest is manually drawn around the tumour along its longer axis to calculate the mean ADC of the tumour. A qualitative assessment of the ADC map shows a decrease in signal intensity at mid-course chemotherapy
Fig. 2
Fig. 2
Flow diagram of participants
Fig. 3
Fig. 3
Box plots comparing apparent diffusion coefficient (ADC) values at MRI acquired at mid-course of chemotherapy (MRI-2). a−c Box plots compare ADC2 values (a), absolute differential ADC2−ADC1 values (b) and ratio (ADC2−ADC1)/ADC1×100 values (c). Good responders have higher mean ADC values and higher increases in ADC from initial to mid-course MRI than poor responders

Similar articles

Cited by

References

    1. Rivera-Valentin RK, Zhu L, Hughes DPM. Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy. Paediatr Drugs. 2015;17:257–271. doi: 10.1007/s40272-015-0134-4. - DOI - PMC - PubMed
    1. Chen W, Lin Y. Nomograms predicting overall survival and cancer-specific survival in osteosarcoma patients (STROBE) Medicine (Baltimore) 2019;98:e16141. doi: 10.1097/MD.0000000000016141. - DOI - PMC - PubMed
    1. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247–263. doi: 10.1007/s10555-009-9186-7. - DOI - PubMed
    1. Gaspar N, Occean B-V, Pacquement H, et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur J Cancer. 2018;88:57–66. doi: 10.1016/j.ejca.2017.09.036. - DOI - PubMed
    1. Gomez-Brouchet A, Bouvier C, Decouvelaere A-V, et al. Place of the pathologist in the management of primary bone tumors (osteosarcoma and Ewing's family tumors after neoadjuvant treatment) Ann Pathol. 2011;31:455–465. doi: 10.1016/j.annpat.2011.10.009. - DOI - PubMed

LinkOut - more resources